Back to Search
Start Over
Hookipa Pharma announces pivotal phase 2/3 trial design for HB-200 in combination with pembrolizumab
- Source :
- PharmaBiz. April 27, 2024
- Publication Year :
- 2024
-
Abstract
- Hookipa Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced its final pivotal phase 2/3 trial design for HB-200 in combination with [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.791787097